Spikes Asia

The New Chapter

McCANN HEALTH, Tokyo / ACTELION / 2019

Awards:

1 Shortlisted Spikes Asia
Film

Overview

Entries

Credits

Overview

Background

Cultural/Context information for the jury In the world including Japan, PAH is a serious disease of the blood vessels with no cure(*1), and 4 out of 10 patients die within 7 years of diagnosis(*2).

Opsumit tablets launched by Actelion, is the one and only drug approved with proven long-term efficacy for PAH treatment.

It has become a treatment option that brings new hope to patients who had to once give up on living their lives and their physicians.

(*1) Vachiéry JL and Gaine S., Eur Respir Rev 2012; 21:313-20.

(*2) Benza RL, et al., Eur Respir Rev 2012; 21:313-20.

Execution

This film has adopted a flip-book animation style to emphasize the patient’s deep emotions as she flips over her life story in her album, and the sentiments she feels as she reflects over each moment.

The scenes of her bright future that is offered through her doctor and the new treatment is illustrated with vivid colors to convey the potential efficacy of the product, which cannot be directly expressed due to Japanese regulations, and the strong hope it brings.

Furthermore, the doctor’s hands wiping the patient’s tears is the only element taken in live-action. This expression was adopted to highlight the doctor’s presence as the key person that supports patients and the meaningfulness of their role.

Similar Campaigns

8 items

The New Chapter

McCANN HEALTH, Tokyo

The New Chapter

2019, ACTELION

(opens in a new tab)